Denileukin diftitox - Eisai
Alternative Names: DAB389IL-2; DAB389 interleukin-2; E7272; E7777; I/ONTAK; Interleukin-2 fusion toxin; LY 335348; LYMPHIRTM; ONTAK; RemitoroLatest Information Update: 20 Aug 2024
At a glance
- Originator Ajinomoto; Japanese Foundation for Cancer Research
- Developer Citius Oncology; Eisai Co Ltd
- Class ADP ribose transferases; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antiretrovirals; Antirheumatics; Bacterial toxins; Interleukins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Phase II Malignant melanoma
- Phase I/II Diffuse large B cell lymphoma
- Discontinued Alopecia; Atopic dermatitis; HIV infections; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 12 Aug 2024 Citius Pharmaceuticals completes the spin-off of denileukin diftitox into its majority-owned oncology company, Citius Oncology
- 08 Aug 2024 Registered for Cutaneous T-cell lymphoma (Second-line therapy or greater) in USA (IV)
- 08 Aug 2024 Citius Pharmaceuticals plans to launch denileukin diftitox for Cutaneous T-cell lymphoma (Second-line therapy or greater) in the USA in 2025